


CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A compound represented by formula 1:



wherein

R¹ is selected from the group consisting of H, halogen, (C₁₋₄)alkyl, O(C₁₋₄)alkyl, and haloalkyl;


R² is H or Me;

R³ is H or (C₁₋₄)alkyl;

R⁴ is H or (C₁₋₄)alkyl;

R⁵ is (C₁₋₄)alkyl, (C₁₋₄)alkyl(C₃₋₇)cycloalkyl, or (C₃₋₇)cycloalkyl; and

W is selected from:




wherein,

a) one of **Y** is SO₂ and the other **Y** is NR⁶, provided that both are not the same, wherein **R⁶** is selected from the group consisting of: H, C(O)O(C₁₋₄)alkyl, (C₁₋₄) alkyl or (C₁₋₄) alkyl substituted with either a pyridinyl-N-oxide or C(O)OR⁸ wherein **R⁸** is H or (C₁₋₄) alkyl; and each **R⁹** is independently H or (C₁₋₄) alkyl; and

b) **E** is $\text{CR}^{10}\text{R}^{10}$ wherein each R^{10} is independently H or (C_{1-4}) alkyl, J is CH_2 and the dotted line represents a single bond; or

c) **E** and **J** are both CR^{11} wherein R^{11} is H or (C_{1-4}) alkyl and the dotted line represents a double bond; or

W is selected from:



wherein,


m is 1 or 2,

R^{12} is H or $\text{C}_{(1-4)}$ alkyl,

R^{13} is H or (C_{1-4}) alkyl, and

Z is **O** or **Z** is NR^{14} wherein R^{14} is H or (C_{1-4}) alkyl; or


W is selected from a group of aromatic radicals consisting of:




wherein R^{15} is (C_{1-4}) alkyl or CF_3 , and n is the integer 0, 1 or 2, or a pharmaceutically acceptable salt or ester thereof.

Claim 2 (original): The compound according to claim 1, wherein R^1 is selected from the group consisting of: H, Cl, F, (C_{1-4}) alkyl and CF_3 ; R^2 , R^3 and R^4 is each independently H or Me; R^5 is ethyl or cyclopropyl;


W is:



wherein **Y** is SO_2 and the other **Y** is NR^6 , provided that both are not the same, R^6 is H, $C(O)OMe$, $C(O)OEt$, (4-pyridinyl-N-oxide)methyl, $CH_2C(O)OH$, $CH_2C(O)OMe$, $CH_2C(O)OEt$ or $CH_2C(O)OCMe_3$, and each R^9 is independently H or Me; or



wherein **E** is $CR^{10}R^{10}$ wherein each of R^{10} is independently H or Me, **J** is CH_2 and the dotted line represents a single bond; or both **E** and **J** are CR^{11} wherein R^{11} is H or Me and the dotted line represents a double bond; one of **Y** is SO_2 and the other **Y** is NR^6 wherein R^6 is hydrogen or methyl; or




wherein R^{15} is Me or Et, and n is 0 or 1.


Claim 3 (original): The compound according to claim 2, wherein R^{15} is Me.

Claim 4 (original): The compound according to claim 3, wherein R^1 is H, Cl, F and Me; R^2 is H or Me;


W is:



Claim 5 (original): The compound according to claim 4, wherein R^3 is Me, R^6 is H, $C(O)OEt$ or (4-pyridinyl-N-oxide)methyl, and **W** is:



Claim 6 (original): The compound according to claim 4, wherein **W** is:



wherein one **Y** is SO₂ and the other **Y** is NR⁶, provided that both are not the same, **R**⁶ is H, C(O)OEt, CH₂C(O)OH, CH₂C(O)OCMe₃, (4-pyridinyl-N-oxide)methyl; and each **R**⁹ is independently H or Me.

Claim 7 (original): The compound according to claim 6, wherein **R**⁶ is H and each **R**⁹ is Me.

Claim 8 (cancelled)

Claim 9 (cancelled)

Claim 10 (cancelled)

Claim 11 (previously presented): A pharmaceutical composition for the treatment of HIV infection, comprising a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt or ester thereof, in combination with a pharmaceutically acceptable carrier.


Claim 12 (previously presented): A method for the treatment of HIV infection, comprising administering to a patient an HIV inhibiting amount of a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt or ester thereof.

Claim 13 (previously presented): A method for the treatment of HIV infection, comprising administering to a patient an HIV inhibiting amount of a pharmaceutical composition according to claim 11.


Claim 14 (currently amended): A process for producing a compound of formula 1



according to claim 1, comprising the step:

- coupling a compound of formula 2:



wherein **R¹**, **R²**, **R³**, **R⁴**, and **R⁵** are as defined in claim 1, with a phenolic derivative selected from:






wherein PG¹ is a nitrogen protecting group and PG² is a carboxy protecting group, said protecting groups being removable under mildly acidic, mildly alkaline or reductive conditions, and **R**⁶, **R**⁹, **R**¹⁰, **R**¹¹, **R**¹², **R**¹³, **R**¹⁴, **R**¹⁵, m, n, and **Z** are as defined in claim 1.

Claim 15 (original): The process according to claim 14, wherein said nitrogen protecting group is selected from: alkyl esters; aralkyl esters; and esters that can be cleaved by mild base treatment or mild reductive means.

Claim 16 (original): The process according to claim 14, wherein said carboxy protecting group is selected from: Boc (*tert*-butoxycarbonyl) and alkyl carbamates.

Claim 17 (original): An intermediate compound of formula 2:



wherein R^1 , R^2 , R^3 , R^4 , and R^5 are as defined in claim 1.